title: Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501.
abstract: OBJECTIVE
  The present study was designed to determine whether adjuvant chemotherapy with paclitaxel (TXL) and carboplatin (CBDCA) after surgical resection is feasible in Japanese patients with non-small cell lung cancer (NSCLC) in a multiinstitutional trial.
  
  
  METHODS
  From August 2005 to March 2006, 34 patients received the following regimen: TXL (175 mg/m2) and CBDCA (AUC = 5) on day 1, every 3 weeks. The primary endpoint of this trial was the completion rate of four cycles.
  
  
  RESULTS
  The completion rate of four cycles was 79.4% [90% confidence interval (CI), 67.5%-91.3%]. Perfect completion rate of four cycles on schedule and full doses without delay was 50% (90% CI, 34.9%-65.1%). The reasons for incomplete cycles were hypersensitivity to TXL infusion during the first cycle in 3 patients, patients refusal in 2, and anemia and cerebral infarction in 1 patient each. As a consequence of delay and/or dose reductions, the relative dose intensity of TXL and CBDCA was 86.2% and 85.8%, respectively.
  
  
  CONCLUSIONS
  Doublet chemotherapy with TXL and CBDCA in the planned doses and schedule was found to be a feasible treatment for Japanese patients following surgical resection for NSCLC:
authors.affiliation: Department of Surgery, Nippon Steel Yawata Memorial Hospital, 1-1-1 Harunomachi, Yahatahigashi-ku, Kitakyushu 805-8508, Japan. maruyama.r@ns.yawata-mhp.or.jp
authors.forename: Riichiroh
authors.initials: R
authors.lastname: Maruyama
authors.forename: Ichiro
authors.initials: I
authors.lastname: Yoshino
authors.forename: Shoji
authors.initials: S
authors.lastname: Tokunaga
authors.forename: Morio
authors.initials: M
authors.lastname: Ohta
authors.forename: Masato
authors.initials: M
authors.lastname: Kato
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshimine
authors.forename: Koji
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakanishi
authors.forename: Yukito
authors.initials: Y
authors.lastname: Ichinose
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011013:Pneumonectomy; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel